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ABSTRACT
Nonalcoholic fatty liver (NAFL) has been reported
to be common among subjects with diabetes.
However, there are not much therapeutic options for
NAFL. In this open labeled clinical trial we studied
the effect of Essentiale in diabetic subjects with NAFL.
Twenty-eight type 2 diabetic patients attending the
out-patient division of M.V. Diabetes Specialities
Centre, Chennai and satisfying the inclusion criteria
were recruited for the study. High resolution B mode
ultrasonography was carried out for diagnosis of
NAFL. Liver funct ion markers [Alanine
aminotransferase (ALT), Aspartate aminotransferase
(AST) and Gamma Glutamyl transferase (GGT)] were
measured. 22 out of the 28 patients (78.5%) were
available for follow up. The mean age of the study
subjects was 41±8 years and 50% were males. A
significant reduction in all the liver enzymes were
observed after Essentiale treatment (baseline vs. six
months after treatment: ALT: 54.5± 29.6 IU/L vs.
37.1±18.7 IU/L, p< 0.05, AST: 38.0±18.0 IU/L vs.
27.6±12.4 IU/L, p< 0.05, GGT: 38.7±27.5 IU/L vs.
29.6±13.8 IU/L, p< 0.05). Ultrasound studies revealed
that the hepatic echotexture improved after Essentiale
treatment in 12/22 (54.5%) of the study subjects, while
there was no change in 9/22 (40.9%), and it worsened
in only one patient (4.5%). The study results suggest
that Essentiale protects and improves liver function
in diabetic subjects with NAFL. Prospective, blinded
clinical trials are required to confirm these findings.
KEY WORDS: Non-alcoholic fatty liver (NAFL);
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INTRODUCTION
The liver plays a major role in the regulation of
carbohydrate metabolism, as it uses glucose as a
fuel, it has the capability to store glucose as glycogen
and also synthesize glucose from non-carbohydrate
sources. This key function of liver makes it vulnerable
to diseases in subjects with metabolic disorders,
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particularly diabetes (1). Nearly 70-80% of the diabetic
subjects have been reported to have hepatic fat
accumulation, referred to as is nonalcoholic fatty liver
(NAFL) (2).  NAFL leads to nonalcohol ic
steatohepatitis (NASH), a progressive fibrotic disease,
which can result in cirrhosis or liver related death (3,4).
Nonalcoholic fatty liver (NAFL) was first reported
in 1980’s in obese females with diabetes. There is
renewed interest recently because of the increased
prevalence of NAFL in diabetes and as it has been
shown to be a predisposing factor for insulin resistance
and hyperinsulinemia (5). Further proof for the
association of liver disease with diabetes comes from
the Insulin Resistance Atherosclerosis Study (IRAS),
which showed that liver function markers like the
Aspartate aminotransferase (AST) and Alanine
aminotransferase (ALT) are predictors of incident
diabetes (6).
Presently there are not much therapeutic options
for nonalcoholic fatty liver except correction of obesity
with hypocaloric diets and physical exercise and
controlling hyperglycemia with diet, insulin, or oral
hypoglycemic agents (7).  Any therapeutic
intervention, which can target fat accumulation and
ameliorate hepatic histology, would be of great benefit.
Essentiale is prepared from Soya beans, and has
phosphatidylcholine as its active ingredient.
Phosphatidylcholine (the main component of lecithin)
is an integral part of cell membranes and is essential
for structural and functional integrity of the cell. It
also enhances cell membrane function throughout the
body and facilitates the movement of fats in and out
of the cells. Though Essentiale is routinely used in
treatment of liver disorders irrespective of the
etiological factor, it’s effects on liver function and
ultrasound appearance of hepatic echotexture in
subjects with diabetes and nonalcoholic fatty liver has
not been explored. This forms the basis of this open
labeled clinical trial in which the effect of Essentiale
was studied in diabetic subjects with nonalcoholic
fatty liver.
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METHODS
Type 2 diabetic patients (n = 28) attending the
out-patient division of Dr. Mohans’ M.V. Diabetes
Specialities Centre, Chennai and satisfying the
inclusion criteria were recruited for the study. The
ethical committee of the hospital approved the study
and informed consent was obtained from all the study
subjects. The inclusion criteria for the study was type
2 diabetic patients within the age range of 25 – 60
years, with NAFL. Patients with liver cirrhosis,
diabetic complication including diabetic ketoacidosis
and history of regular alcohol consumption were
excluded from the study.
Diabetes was diagnosed based on drug treatment
for diabetes (insulin or oral hypoglycemic agents) and/
or criteria laid by the WHO Consultation Group report
i.e. fasting plasma glucose (FPG) ³ 126 mg/dl or 2 hr
post glucose value ³ 200 mg/dl (8).
High resolution B mode ultrasonography (Logic
400 GE, Milwaukee, U.S.A.) was carried out for
diagnosis of NAFL by a well trained ultrasonologist
who was masked to the patient status or the indication
for the ultrasound. Liver texture was graded as follows:
Grade 1: a slight diffuse increase in fine echoes
in the hepatic parenchyma with normal visualization
of the diaphragm and intrahepatic vessel borders.
Grade 2: a moderate diffuse increase in fine
echoes with slightly impaired visualization of the
intrahepatic vessels and diaphragm
Grade 3: a marked increase in fine echoes with
poor or no visualization of the intrahepatic vessel
borders, diaphragm and posterior portion of the right
lobe of the liver (9).
In order to assess reproducibility of the grading
the ultrasound was repeated within a week in 6
subjects. The kappa value between the two tests was
0.75 indicating excellent reproducibility.
28 type 2 diabetic patients who satisfied the
inclusion and exclusion criteria were taken up for the
study. They were initiated on Essentiale therapy (2
tablets of 350 mg – three times a day). Patients
received a standard diabetic diet of High Carbohydrate
High Fibre (HCHF) as described earlier (10). The diet
was kept constant throughout the study. A dietitian
checked the adherence to the diet at each visit to
ensure that it was kept constant throughout the study.
Subjects were provided the antidiabetic treatment
depending upon the severity of the disease (glycemic
level). If patient was on fibrates or statins, the dose
of these was kept constant throughout the study. All
subjects were requested to undertake a battery of
tests during each follow up visit (once in two months)
for a total period of six months.
Patient’s clinical history was recorded at baseline.
At each follow-up visit, the blood pressure was
recorded. Fasting plasma glucose (glucose oxidase-
peroxidase method, Roche Diagnostics, Mannheim,
Germany) serum cholesterol (cholesterol oxidase-
peroxidase-amidopyrine method, Roche Diagnostics,
Mannheim, Germany), serum triglycerides (glycerol
phosphate oxidase-peroxidase-amidopyrine method,
Roche Diagnostics,Mannheim, Germany) and HDL
cholesterol (direct method–polyethylene glycol-
pretreated enzymes, Roche Diagnostics, Mannheim,
Germany) were measured using Hitachi-912
Autoanalyser (Hitachi, Mannheim, Germany). The
intra and inter assay co-efficient of variation for the
biochemical assays ranged from 3.1% to 7.6%. Low-
density lipoprotein (LDL) cholesterol was calculated
using the Friedewald formula (11). Glycated
hemoglobin (HbA1c) was estimated by high-pressure
liquid chromatography using the Variant machine (Bio-
Rad, Hercules, USA). The intra and inter assay co-
efficient of variation of HbA1c was <10%.
Liver function markers measured were Alanine
aminotransferase (ALT), Aspartate aminotransferase
(AST) and Gamma Glutamyl transferase (GGT) was
estimated in Hitachi 912 Autoanalyser (Hitachi,
Mannheim, Germany). The intra and inter assay
precision of these assays ranged from 3.6% to 7.5%.
Ultrasound assessment of hepatic echotexture
was done at baseline and six months after treatment.
Statistical Analysis: Data were computed in MS
excel data sheet.  Paired ‘t’ test was used to compare
the data among different visits. All analyses were done
using Windows based SPSS statistical package
(Version 10.0, Chicago) and p values <0.05 were taken
as significant.
RESULTS
22 out of the 28 patients (78.5%) were available
for follow up. 6 patients dropped out for various reasons
(3 patients changed their residence, 3 were unable
to come for the last visit for personal reasons). Of the
22 patients, 5 (22.7%) were on metformin therapy, 5
(22.7%) were on a sulphonylurea and 10 (45.5%) were
on combination of both, while 2 (9.0%) were on insulin
therapy. 4 (16.6%) patients were on a statin and 2
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(8.3%) on fibrate. Step up or anti-diabetic drug doses
were done in 6 (27.3%) pat ients to control
hyperglycemia, but the drugs were not changed.
The mean age of the study subjects was 41±8
years. There were 11 (50.0%) males and the mean
body mass index was 28.2 kg/m2. Table 1 shows the
clinical characteristics of the study subjects before
and after treatment. Significant decrease in fasting
plasma glucose (p = 0.007), HbA1c (p = 0.001) and
total cholesterol (p = 0.046) were observed after the
treatment.
Table 1: Clinical and Biochemical Characteristics
of the Study Subjects Before and After Treatment
Parameters Before After p value
Treatment Treatment
(n = 22) (n = 22)
Systolic blood pressure (mm Hg) 124 ± 12 119 ± 11 0.070
Diastolic blood pressure (mm Hg) 79 ± 8 74 ± 8 0.003
Fasting plasma glucose (mg/dl) 164 ± 77 121 ± 25 0.007
Glycated hemoglobin (%) 8.5 ± 2.6 6.7 ± 0.9 0.001
Total cholesterol (mg/dl) 191 ± 42 173 ± 36 0.046
Serum triglycerides (mg/dl) 217 ± 151 169 ± 87 0.086
LDL cholesterol (mg/dl) 112 ± 34 99 ± 28 0.057
Fig 1 presents the results of ultrasound hepatic
echotexture of the study subjects before and after
treatment. At baseline, 18.2% (4/22) were diagnosed
as Grade 1, 45.5% (10/22) as Grade 2 and 36.4% (8/
22) as Grade 3. Among those with Grade 1, 50% (2/
4) showed an improvement in echotexture, while 25%
(1/4) showed no change and in 25% (1/4), it worsened.
Among subjects with Grades 2 and 3, 41.7% (5/12)
and 83.3% (5/6) respectively showed improvement.
Overall 54.5% (12/22) showed improvement, 40.9%
(9/22) of the study subjects showed no change in
hepatic echotexture, and in only one patient (4.5%),
it worsened.
Fig 1: Effect of Essentiale on Hepatic Echotexture
Fig 2 shows the liver function markers in the study
subjects during the various visits. As observed from
the graph, there was a significant reduction in all the
liver enzymes after Essentiale treatment
Fig 2: Mean Levels of ALT, AST and GGT in the
Study Subjects
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Table 2 presents the liver enzyme levels according
to different grades of baseline hepatic echotexture of
the study subjects. In the total study subjects,
significant decrease was observed in ALT (p = 0.007),
AST (p = 0.004), and GGT (p = 0.024) values, six
months after treatment with Essentiale. Liver function
markers did not show any alteration in Grade 1
subjects while those in Grades 2 and 3 all hepatic
enzymes showed a marked reduction after treatment.
However, the differences did not reach statistical
significance owing to small sample size. Liver function
markers were also compared according to the
changes in hepatic echotexture after treatment. Even
among subjects who did not show any change in
echotexture, a decrease in all enzymes was observed.
None of the study subjects had any adverse reactions
to the drug.
DISCUSSION
NAFL and NASH are reported to be the most
common cause of chronic liver disease in the U.S.
with a prevalence rate ranging between 10 – 24%.
NAFL is characterized by steatosis, periportal and
lobular inflammation (7). Most often, NAFL remains
asymptomatic. It is twice as common among diabetic
subjects compared to non-diabetic subjects. An Italian
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study showed that 10.5% of the subjects who had
elevated AST and ALT had diabetes (12). A similar
study in Cleveland showed that nearly 33% of subjects
with NASH had diabetes (13).
NAFL is usually innocuous but in some patients
it could result in cirrhosis, liver failure and cancer (7).
Currently, there have been no well-proven therapies
for treatment of NASH. However, some studies have
explored the efficacy of glitazones, vitamin E,
probucol, atorvastatin and alternative therapies like
betaine, and have shown some beneficial results
(14 - 17).
In this study, Essentilae, which essentially
contains phosphatidylcholine, seems to be effective
in reducing the liver function markers and altering the
hepatic echotexture favorably in diabetic subjects with
non-alcoholic fatty liver.
Fasting plasma glucose and glycated hemoglobin
were significantly reduced in the study subjects after
treatment. This is probably due to the step up in doses
of anti-diabetic therapy. Liver function markers,
particularly ALT and AST showed a significant
reduction even within two months of treatment
(Fig 2), while GGT showed a significant reduction only
after six months of treatment.
Ultrasound assessment of hepatic echotexture
showed favorable results with nearly 50% of subjects
showing improvement in hepatic echotexture.
Subjects with more severe hepatic changes benefited
more with Essentiale treatment as more than 80% of
subjects with grade 3 showed an improvement in
hepatic echotexture while among grade 1 subjects
only 50% showed favorable changes.
It is of interest that even among subjects who failed
to show any change in the echotexture after
treatment, the liver function markers showed a
significant decrease indicating that Essentiale
improves liver function even in those without obvious
structural  improvement.  Another interest ing
observation in this study was that subjects with more
severe grades of NAFL as diagnosed by ultrasound
had marked reduction in liver enzymes than those
with lesser grading. These data suggest that
Essentiale may in fact offer more benefit to diabetic
subjects with severe grades of NAFL.
Earlier, in an open label study in children below
16 years with non-alcoholic fatty liver, Vitamin E was
shown to normalize ALT and alkaline phosphatases
(14). A recent prospective double-blind study showed
that both vitamin E and C were effective in improving
hepatic fibrosis scores (18). Metformin therapy
transiently improved liver function markers in a open
labeled trial while a randomized clinical trial showed
Table 2: ALT, AST and GGT Levels Before and After Treatment in the Study Subjects
Parameters ALT AST GGT
Before After Before After Before After
Treatment Treatment Treatment  Treatment Treatment Treatment
Overall 54.5 ± 29.6 37.1 ± 18.7 ** 38.0 ± 18.0 27.6 ± 12.4 ** 38.7 ± 27.5 29.6 ± 13.8 **
Categorized According to Baseline Ultrasound Hepatic Echotexture
Grade 1 37.8 ± 11.0 37.8 ± 15.2 28.3 ± 8.6 28.0 ± 15.0 24.5 ± 7.6 26.0 ± 2.9
Grade 2 58.5 ± 35.4 39.6 ± 23.1 40.5 ± 20.6 28.8 ± 12.5 * 43.1 ± 35.4 31.7 ± 17.5
Grade 3 57.5 ± 23.9 31.8 ± 10.5 39.3 ± 17.0 24.8 ± 12.5 39.5 ± 12.9 27.8 ± 9.7
Categorized According to Changes in Ultrasound Hepatic Echotexture After Treatment
Improved 47.9 ± 28.0 24.8 ± 6.7 ** 32.4 ± 16.3 19.8 ± 2.8 * 29.2 ± 15.2 22.8 ± 8.2
No Change 65.9 ± 30.6 53.2 ± 18.4 47.1 ± 17.8 38.4 ± 12.9 53.8 ± 34.9 38.7 ± 15.7
* p < 0.05, ** p<0.01 compared to before treatment
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that improvement of insulin sensitivity occurs with
improvement in the liver function in subjects with NAFL
(19, 20).
Choline deficient diet has been observed to cause
hepatitis in mice, which resembles that in humans
(21). I t  is more reasonable to presume that
phosphatidylcholine supplementation could be of
benefi t  to subjects with hepat i t is.
Polyenephosphatidyl choline extract from soyabean
has been approved for the treatment of chronic liver
diseases in many European countr ies
( h t t p : / / w w w. l e f . o r g / m a g a z i n e / m a g 2 0 0 4 /
feb2004_report_liver_02.htm) Phosphatidylcholine
gets incorporated into the cell membrane of both
normal and damaged liver cell in animal models (21),
the end result being an increase in membrane fluidity
and active transport across the membrane. Similarly,
i t  has been suggested that incorporat ion of
phosphatidylcholine into blood lipoprotein results in
lipid-lowering properties. In the present study, a
significant reduction in LDL cholesterol was observed
after treatment with Essentiale. This is in agreement
with a clinical trial in Russia where supplement of
phosphatidylcholine lowered total and LDL cholesterol
by about 15%, decreased triglyceride levels by 32%,
and raised levels of HDL cholesterol by 10% (22).
However, in the present study one cannot rule out
the fact that improved glycemic control as observed
from HbA1c reduction could have caused the
improvement in lipid levels.
In addit ion, l ike vi tamin E and C,
phosphatidylcholine also appears to have antioxidant
properties, which means it may effectively reduce the
oxidative stress shown to be a contributing factor in
the inflammation and scarring of nonalcoholic
steatohepatitis (23).
To conclude, the data suggests that Essentiale
protects and improves liver function in diabetic
subjects with NAFL. In order to confirm these findings
and to determine its mechanism of action, prospective,
randomized blinded clinical trials are needed.
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